Vestal Point Capital’s Lexeo Therapeutics LXEO Stock Holding History

Vestal Point Capital’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.1M	Sell	4,320,000 -155,000	-3%	-$838K	0.47%	45
2026 Q1	$25.7M	Hold	4,475,000	–	–	0.72%	45
2025 Q4	$44.4M	Buy	4,475,000 +1,225,000	+38%	+$11.2M	1.51%	21
2025 Q3	$21.6M	Buy	3,250,000 +21,839	+0.7%	+$106K	0.97%	39
2025 Q2	$13M	Buy	3,228,161 +2,091,912	+184%	+$6.88M	0.68%	42
2025 Q1	$3.94M	Sell	1,136,249 -63,751	-5%	-$282K	0.28%	47
2024 Q4	$7.9M	Buy	1,200,000 +350,000	+41%	+$2.76M	0.47%	46
2024 Q3	$7.68M	Buy	850,000 +10,000	+1%	+$119K	0.58%	40
2024 Q2	$13.5M	Buy	840,000 +665,000	+380%	+$9.66M	1%	30
2024 Q1	$2.74M	Buy	+175,000	New	+$2.74M	0.23%	49

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vestal Point Capital's LXEO Position: Q2 2026 in Review

Vestal Point Capital reduced its Lexeo Therapeutics (LXEO) stake by 3.5% in Q2 2026, selling an estimated $838K and leaving 4,320,000 shares worth $20.1M. The position accounts for 0.47% of the portfolio, ranked #45.

Vestal Point Capital first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $44.4M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Vestal Point Capital held 4,320,000 shares of Lexeo Therapeutics worth $20.1M as of Q2 2026.
Vestal Point Capital sold 155,000 Lexeo Therapeutics shares in Q2 2026, an estimated $838K.
Lexeo Therapeutics made up 0.47% of Vestal Point Capital's portfolio in Q2 2026, its #45 holding.
Vestal Point Capital first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
Vestal Point Capital's Lexeo Therapeutics position peaked at $44.4M in Q4 2025.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.